Journal of Clinical Medicine (Nov 2022)

Pregnancy and COVID-19

  • Thomas Ntounis,
  • Ioannis Prokopakis,
  • Antonios Koutras,
  • Zacharias Fasoulakis,
  • Savia Pittokopitou,
  • Asimina Valsamaki,
  • Athanasios Chionis,
  • Evangelia Kontogeorgi,
  • Vasiliki Lampraki,
  • Andria Peraki,
  • Athina A. Samara,
  • Sevasti-Effraimia Krouskou,
  • Konstantinos Nikolettos,
  • Panagiotis Papamichalis,
  • Alexandros Psarris,
  • Vasilios Pergialiotis,
  • Marianna Theodora,
  • Panos Antsaklis,
  • Alexandros Daponte,
  • Georgios Daskalakis,
  • Emmanuel N. Kontomanolis

DOI
https://doi.org/10.3390/jcm11226645
Journal volume & issue
Vol. 11, no. 22
p. 6645

Abstract

Read online

Evidence indicates that SARS-CoV-2 infection increases the likelihood of adverse pregnancy outcomes. Modifications in the circulatory, pulmonary, hormonal, and immunological pathways induced by pregnancy render pregnant women as a high-risk group. A growing body of research shows that SARS-CoV-2 infection during pregnancy is connected to a number of maternal complications, including pneumonia and intensive care unit (ICU) hospitalization. Miscarriages, stillbirth, preterm labor, as well as pre-eclampsia and intrauterine growth restriction are also among the most often documented fetal implications, particularly among expecting women who have significant COVID-19 symptoms, often affecting the timing and route of delivery. Thus, prevention of infection and pharmacological treatment options should aim to minimize the aforementioned risks and ameliorate maternal, obstetric and fetal/neonatal outcomes.

Keywords